NCT04438304View on ClinicalTrials.gov

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

November 26, 2024

Study Completion Date

November 26, 2024

Conditions
Neuroendocrine Tumors
Interventions
DRUG

64Cu-SARTATE

64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.

Trial Locations (4)

2065

Royal North Shore Hospital, Sydney

2751

Nepean Hospital, Kingswood

3000

Peter MacCallum Cancer Centre, Melbourne

5000

Royal Adelaide Hospital, Adelaide

Sponsors
All Listed Sponsors
lead

Clarity Pharmaceuticals Ltd

INDUSTRY